Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 5/20 | 0.43 |
| ▸ | MTNR1B | P49286 | 5/20 | 0.43 |
| ▸ | PDE4A | P27815 | 2/20 | 0.40 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.40 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.40 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.40 |
| ▸ | CES2 | O00748 | 1/20 | 0.38 |
| ▸ | CES1 | P23141 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7923323 | 1.00 | MTNR1A (0.43) | MTNR1AMTNR1BPDE4APDE4BPDE4C | |
| SCHEMBL7923233 | 0.86 | MTNR1A (0.56) | MTNR1AMTNR1BPDE4APDE4BPDE4C | |
| SCHEMBL7923230 | 0.86 | MTNR1A (0.56) | MTNR1AMTNR1BPDE4APDE4BPDE4C | |
| SCHEMBL7925193 | 0.85 | SLC6A1 (0.40) | NPC1RAB9AKMT2A | |
| SCHEMBL7925198 | 0.85 | SLC6A1 (0.40) | NPC1RAB9AKMT2A | |
| SCHEMBL7917611 | 0.82 | SLC6A1 (0.34) | — | |
| SCHEMBL7923055 | 0.81 | MTNR1A (0.47) | MTNR1AMTNR1BPDE4APDE4BPDE4C | |
| SCHEMBL7923057 | 0.81 | MTNR1A (0.47) | MTNR1AMTNR1BPDE4APDE4BPDE4C | |
| SCHEMBL7917680 | 0.79 | PDE4A (0.50) | MTNR1AMTNR1BPDE4APDE4BPDE4C | |
| SCHEMBL7917677 | 0.79 | PDE4A (0.50) | MTNR1AMTNR1BPDE4APDE4BPDE4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6174898-B1 | TREATING FILARIAE IN LYMPHATIC SYSTEM BY ADMINISTERING N-SUBSTITUTED AZAHETEROCYCLIC CARBOXYLIC ACIDS AND ESTERS IN WHICH A SUBSTITUTED ALKYL CHAIN FORMS PART OF N-SUBSTITUENT AND SALTS | NOVO NORDISK A/S (DK) | 2001-01-16 | — | — | US | disclosed |
| EP-0858339-A1 | A METHOD OF TREATING FILARIAE | NOVO NORDISK A/S (DK) | 1998-08-19 | — | — | EP | disclosed |
| EP-0502031-B1 | N-SUBSTITUTED AZAHETEROCYCLIC CARBOXYLIC ACIDS AND A PHARMACEUTICAL COMPOSITION | NOVO NORDISK AS (DK) | 1997-08-20 | — | — | EP | disclosed |
| WO-1997017073-A1 | A METHOD OF TREATING FILARIAE | NOVO NORDISK A/S (DK) | 1997-05-15 | — | — | WO | disclosed |
| US-5198451-A | Treatment of epilepsy, inhibitors of gamma-aminobutyric acid uptake from synaptic cleft | NOVO NORDISK A/S (DK) | 1993-03-30 | — | — | US | disclosed |
| EP-0502031-A1 | N-SUBSTITUTED AZAHETEROCYCLIC CARBOXYLIC ACIDS AND A PHARMACEUTICAL COMPOSITION. | NOVO NORDISK AS (DK) | 1992-09-09 | — | — | EP | disclosed |
| WO-1991007389-A1 | N-SUBSTITUTED AZAHETEROCYCLIC CARBOXYLIC ACIDS AND A PHARMACEUTICAL COMPOSITION | NOVO NORDISK A/S (DK) | 1991-05-30 | — | — | WO | disclosed |